XNAS 16 Oct, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Dr. Mary C. Beckerle, PhD | Director | Sale of securities on an exchange or to another person at price $ 53.66 per share. | 10 Aug 2026 | 9,812 | 16,079 (0%) | 0% | 53.7 | 526,512 | Common Stock |
| Mr. Jack L. Wyszomierski, M.S. | Director | Sale of securities on an exchange or to another person at price $ 50.55 per share. | 01 Jun 2026 | 3,925 | 284,384 (0%) | 0% | 50.6 | 198,409 | Common Stock |
| Dr. Sue Gail Eckhardt, M.D. | Director | Sale of securities on an exchange or to another person at price $ 50.14 per share. | 01 Jun 2026 | 9,812 | 16,079 (0%) | 0% | 50.1 | 491,974 | Common Stock |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2026 | 8,367 | 127,199 (0%) | 0% | 0 | Common Stock | |
| Mr. Jack L. Wyszomierski, M.S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2026 | 8,367 | 288,309 (0%) | 0% | 0 | Common Stock | |
| Dr. Stelios Papadopoulos,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2026 | 8,367 | 1,197,595 (0%) | 0% | 0 | Common Stock | |
| Dr. Mary C. Beckerle, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2026 | 8,367 | 25,891 (0%) | 0% | 0 | Common Stock | |
| Dr. Maria C. Freire, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2026 | 8,367 | 109,186 (0%) | 0% | 0 | Common Stock | |
| Ms. Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2026 | 8,367 | 28,957 (0%) | 0% | 0 | Common Stock | |
| Mr. Bob Oliver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2026 | 8,367 | 29,487 (0%) | 0% | 0 | Common Stock | |
| Mr. Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2026 | 8,367 | 50,649 (0%) | 0% | 0 | Common Stock | |
| Dr. Sue Gail Eckhardt, M.D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2026 | 8,367 | 25,891 (0%) | 0% | 0 | Common Stock | |
| Dr. Dana T. Aftab, PhD | EVP, Research and Development | Sale of securities on an exchange or to another person at price $ 50.35 per share. | 26 May 2026 | 43,451 | 594,741 (0%) | 0% | 50.4 | 2,187,758 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 49.81 per share. | 20 May 2026 | 32,110 | 357,638 (0%) | 0% | 49.8 | 1,599,399 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 15 May 2026 | 124,047 | 2,004,327 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 15 May 2026 | 124,047 | 1,362,008 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.10 per share. | 15 May 2026 | 128,497 | 1,486,055 (0%) | 0% | 51.1 | 6,566,197 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.10 per share. | 15 May 2026 | 40,892 | 987,218 (0%) | 0% | 51.1 | 2,089,581 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 15 May 2026 | 34,901 | 952,317 (0%) | 0% | 50 | 1,745,050 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.10 per share. | 15 May 2026 | 33,265 | 389,748 (0%) | 0% | 51.1 | 1,699,842 | Common Stock |
| Dr. Dana T. Aftab, PhD | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.10 per share. | 15 May 2026 | 30,578 | 638,192 (0%) | 0% | 51.1 | 1,562,536 | Common Stock |
| Dr. Brenda Hefti, J.D.,PhD | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.10 per share. | 15 May 2026 | 6,411 | 113,387 (0%) | 0% | 51.1 | 327,602 | Common Stock |
| Dr. Brenda Hefti, J.D.,PhD | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 50.21 per share. | 15 May 2026 | 6,625 | 106,762 (0%) | 0% | 50.2 | 332,641 | Common Stock |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Sale of securities on an exchange or to another person at price $ 45.71 per share. | 07 May 2026 | 60,000 | 118,832 (0%) | 0% | 45.7 | 2,742,600 | Common Stock |
| Dr. Mary C. Beckerle, PhD | Director | 07 May 2026 | 3,856 | 12,854 | - | - | Option (right to buy) | ||
| Dr. Mary C. Beckerle, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.24 per share. | 07 May 2026 | 3,856 | 25,236 (0%) | 0% | 23.2 | 89,613 | Common Stock |
| Dr. Mary C. Beckerle, PhD | Director | Sale of securities on an exchange or to another person at price $ 48.45 per share. | 07 May 2026 | 7,712 | 17,524 (0%) | 0% | 48.4 | 373,646 | Common Stock |
| Dr. Maria C. Freire, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 07 May 2026 | 20,634 | 121,453 (0%) | 0% | 19.8 | 407,934 | Common Stock |
| Dr. Maria C. Freire, PhD | Director | 07 May 2026 | 20,634 | 0 | - | - | Option (right to buy) | ||
| Dr. Maria C. Freire, PhD | Director | Sale of securities on an exchange or to another person at price $ 46.00 per share. | 07 May 2026 | 20,634 | 100,819 (0%) | 0% | 46 | 949,164 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 06 May 2026 | 109,676 | 1,880,280 (0%) | 0% | 0 | Common Stock | |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 52,018 | 1,028,110 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 40,459 | 422,367 (0%) | 0% | 0 | Common Stock | |
| Dr. Dana T. Aftab, PhD | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 52,018 | 668,124 (0%) | 0% | 0 | Common Stock | |
| Dr. Brenda Hefti, J.D.,PhD | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 23,119 | 119,631 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 40,459 | 422,367 (0%) | 0% | 0 | - | |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 52,018 | 1,028,110 (0%) | 0% | 0 | - | |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 40,459 | 422,367 (0%) | 0% | 0 | - | |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 52,018 | 1,028,110 (0%) | 0% | 0 | - | |
| Dr. Dana T. Aftab, PhD | EVP, Research and Development | Sale of securities on an exchange or to another person at price $ 44.50 per share. | 24 Feb 2026 | 47,918 | 616,106 (0%) | 0% | 44.5 | 2,132,351 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2026 | 160,437 | 1,614,552 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Feb 2026 | 100,278 | 1,989,956 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Feb 2026 | 100,278 | 1,989,956 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2026 | 160,437 | 1,614,552 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Feb 2026 | 100,278 | 1,989,956 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2026 | 160,437 | 1,614,552 (0%) | 0% | 0 | - | |
| Dr. Dana T. Aftab, PhD | EVP, Research and Development | Sale of securities on an exchange or to another person at price $ 44.35 per share. | 19 Feb 2026 | 29,873 | 664,024 (0%) | 0% | 44.4 | 1,324,868 | Common Stock |
| Mr. Jack L. Wyszomierski, M.S. | Director | Sale of securities on an exchange or to another person at price $ 44.01 per share. | 18 Feb 2026 | 99,574 | 279,942 (0%) | 0% | 44.0 | 4,382,252 | Common Stock |
| Mr. Jack L. Wyszomierski, M.S. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 18 Feb 2026 | 20,634 | 379,516 (0%) | 0% | 19.8 | 407,934 | Common Stock |
| Mr. Jack L. Wyszomierski, M.S. | Director | 18 Feb 2026 | 20,634 | 0 | - | - | Option (right to buy) | ||
| Mr. Jack L. Wyszomierski, M.S. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 18 Feb 2026 | 20,634 | 379,516 (0%) | 0% | 19.8 | 407,934 | - |
| Mr. Jack L. Wyszomierski, M.S. | Director | Sale of securities on an exchange or to another person at price $ 44.01 per share. | 18 Feb 2026 | 99,574 | 279,942 (0%) | 0% | 44.0 | 4,382,252 | - |
| Mr. Jack L. Wyszomierski, M.S. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 18 Feb 2026 | 20,634 | 379,516 (0%) | 0% | 19.8 | 407,934 | - |
| Mr. Jack L. Wyszomierski, M.S. | Director | Sale of securities on an exchange or to another person at price $ 44.01 per share. | 18 Feb 2026 | 99,574 | 279,942 (0%) | 0% | 44.0 | 4,382,252 | - |
| Ms. Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.19 per share. | 17 Feb 2026 | 42,422 | 63,012 (0%) | 0% | 18.2 | 771,656 | Common Stock |
| Ms. Julie Anne Smith | Director | 17 Feb 2026 | 20,030 | 0 | - | - | Option (right to buy) | ||
| Ms. Julie Anne Smith | Director | 17 Feb 2026 | 44,087 | 0 | - | - | Option (right to buy) | ||
| Ms. Julie Anne Smith | Director | 17 Feb 2026 | 42,422 | 0 | - | - | Option (right to buy) | ||
| Ms. Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 44.30 per share. | 17 Feb 2026 | 20,030 | 20,590 (0%) | 0% | 44.3 | 887,329 | Common Stock |
| Ms. Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.69 per share. | 17 Feb 2026 | 20,030 | 40,620 (0%) | 0% | 21.7 | 434,451 | Common Stock |
| Ms. Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 44.50 per share. | 17 Feb 2026 | 44,087 | 20,590 (0%) | 0% | 44.5 | 1,961,872 | Common Stock |
| Ms. Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 17 Feb 2026 | 44,087 | 64,677 (0%) | 0% | 19.4 | 854,847 | Common Stock |
| Ms. Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 43.33 per share. | 17 Feb 2026 | 42,422 | 20,590 (0%) | 0% | 43.3 | 1,838,145 | Common Stock |
| Ms. Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.19 per share. | 17 Feb 2026 | 42,422 | 63,012 (0%) | 0% | 18.2 | 771,656 | - |
| Ms. Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 43.33 per share. | 17 Feb 2026 | 42,422 | 20,590 (0%) | 0% | 43.3 | 1,838,145 | - |
| Ms. Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 17 Feb 2026 | 44,087 | 64,677 (0%) | 0% | 19.4 | 854,847 | - |
| Ms. Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 44.50 per share. | 17 Feb 2026 | 44,087 | 20,590 (0%) | 0% | 44.5 | 1,961,872 | - |
| Ms. Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.69 per share. | 17 Feb 2026 | 20,030 | 40,620 (0%) | 0% | 21.7 | 434,451 | - |
| Ms. Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 44.30 per share. | 17 Feb 2026 | 20,030 | 20,590 (0%) | 0% | 44.3 | 887,329 | - |
| Ms. Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.19 per share. | 17 Feb 2026 | 42,422 | 63,012 (0%) | 0% | 18.2 | 771,656 | - |
| Ms. Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 43.33 per share. | 17 Feb 2026 | 42,422 | 20,590 (0%) | 0% | 43.3 | 1,838,145 | - |
| Ms. Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 17 Feb 2026 | 44,087 | 64,677 (0%) | 0% | 19.4 | 854,847 | - |
| Ms. Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 44.50 per share. | 17 Feb 2026 | 44,087 | 20,590 (0%) | 0% | 44.5 | 1,961,872 | - |
| Ms. Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.69 per share. | 17 Feb 2026 | 20,030 | 40,620 (0%) | 0% | 21.7 | 434,451 | - |
| Ms. Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 44.30 per share. | 17 Feb 2026 | 20,030 | 20,590 (0%) | 0% | 44.3 | 887,329 | - |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 15 Feb 2026 | 31,483 | 449,722 (0%) | 0% | 43.9 | 1,382,733 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 43.50 per share. | 15 Feb 2026 | 64,778 | 381,908 (0%) | 0% | 43.5 | 2,817,843 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 43.84 per share. | 15 Feb 2026 | 3,036 | 446,686 (0%) | 0% | 43.8 | 133,098 | Common Stock |
| Dr. Dana T. Aftab, PhD | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 15 Feb 2026 | 12,720 | 693,897 (0%) | 0% | 43.9 | 558,662 | Common Stock |
| Dr. Dana T. Aftab, PhD | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 15 Feb 2026 | 26,485 | 706,617 (0%) | 0% | 43.9 | 1,163,221 | Common Stock |
| Dr. Brenda Hefti, J.D.,PhD | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 15 Feb 2026 | 5,430 | 115,181 (0%) | 0% | 43.9 | 238,486 | Common Stock |
| Dr. Brenda Hefti, J.D.,PhD | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 44.01 per share. | 15 Feb 2026 | 18,669 | 96,512 (0%) | 0% | 44.0 | 821,623 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 15 Feb 2026 | 31,483 | 449,722 (0%) | 0% | 43.9 | 1,382,733 | - |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 43.84 per share. | 15 Feb 2026 | 3,036 | 446,686 (0%) | 0% | 43.8 | 133,098 | - |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 43.50 per share. | 15 Feb 2026 | 64,778 | 381,908 (0%) | 0% | 43.5 | 2,817,843 | - |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 15 Feb 2026 | 31,483 | 449,722 (0%) | 0% | 43.9 | 1,382,733 | - |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 43.84 per share. | 15 Feb 2026 | 3,036 | 446,686 (0%) | 0% | 43.8 | 133,098 | - |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 43.50 per share. | 15 Feb 2026 | 64,778 | 381,908 (0%) | 0% | 43.5 | 2,817,843 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Feb 2026 | 250,736 | 1,579,209 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 13 Feb 2026 | 120,390 | 1,829,945 (0%) | 0% | 43.9 | 5,287,529 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 13 Feb 2026 | 369,606 | 1,950,335 (0%) | 0% | 43.9 | 16,233,096 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.31 per share. | 13 Feb 2026 | 494,700 | 2,319,941 (0%) | 0% | 21.3 | 10,542,057 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Feb 2026 | 125,094 | 2,090,234 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | 13 Feb 2026 | 494,700 | 0 | - | - | Option (right to buy) | ||
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Feb 2026 | 125,094 | 1,454,115 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Feb 2026 | 250,736 | 1,965,140 (0%) | 0% | 0 | Common Stock | |
| Mr. Christopher J. Senner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 43.00 per share. | 13 Feb 2026 | 34,278 | 1,042,579 (0%) | 0% | 43 | 1,473,954 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 13 Feb 2026 | 35,870 | 1,006,709 (0%) | 0% | 43.9 | 1,575,410 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 43.67 per share. | 13 Feb 2026 | 30,617 | 976,092 (0%) | 0% | 43.7 | 1,337,044 | Common Stock |
| Mr. Bob Oliver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.28 per share. | 13 Feb 2026 | 9,088 | 51,370 (0%) | 0% | 19.3 | 175,217 | Common Stock |
| Mr. Bob Oliver | Director | 13 Feb 2026 | 9,088 | 12,118 | - | - | Option (right to buy) | ||
| Mr. Bob Oliver | Director | Sale of securities on an exchange or to another person at price $ 43.90 per share. | 13 Feb 2026 | 21,162 | 21,120 (0%) | 0% | 43.9 | 929,012 | Common Stock |
| Mr. Bob Oliver | Director | Sale of securities on an exchange or to another person at price $ 43.61 per share. | 13 Feb 2026 | 9,088 | 42,282 (0%) | 0% | 43.6 | 396,328 | Common Stock |
| Dr. Sue Gail Eckhardt, M.D. | Director | Sale of securities on an exchange or to another person at price $ 43.79 per share. | 13 Feb 2026 | 3,856 | 17,524 (0%) | 0% | 43.8 | 168,854 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.31 per share. | 13 Feb 2026 | 494,700 | 2,319,941 (0%) | 0% | 21.3 | 10,542,057 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 13 Feb 2026 | 369,606 | 1,950,335 (0%) | 0% | 43.9 | 16,233,096 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 13 Feb 2026 | 120,390 | 1,829,945 (0%) | 0% | 43.9 | 5,287,529 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Feb 2026 | 250,736 | 1,579,209 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Feb 2026 | 250,736 | 1,965,140 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Feb 2026 | 125,094 | 1,454,115 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Feb 2026 | 125,094 | 2,090,234 (0%) | 0% | 0 | - | |
| Mr. Christopher J. Senner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 43.00 per share. | 13 Feb 2026 | 34,278 | 1,042,579 (0%) | 0% | 43 | 1,473,954 | - |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 13 Feb 2026 | 35,870 | 1,006,709 (0%) | 0% | 43.9 | 1,575,410 | - |
| Mr. Christopher J. Senner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 43.67 per share. | 13 Feb 2026 | 30,617 | 976,092 (0%) | 0% | 43.7 | 1,337,044 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.31 per share. | 13 Feb 2026 | 494,700 | 2,319,941 (0%) | 0% | 21.3 | 10,542,057 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 13 Feb 2026 | 369,606 | 1,950,335 (0%) | 0% | 43.9 | 16,233,096 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 13 Feb 2026 | 120,390 | 1,829,945 (0%) | 0% | 43.9 | 5,287,529 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Feb 2026 | 250,736 | 1,579,209 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Feb 2026 | 250,736 | 1,965,140 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Feb 2026 | 125,094 | 1,454,115 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Feb 2026 | 125,094 | 2,090,234 (0%) | 0% | 0 | - | |
| Mr. Christopher J. Senner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 43.00 per share. | 13 Feb 2026 | 34,278 | 1,042,579 (0%) | 0% | 43 | 1,473,954 | - |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.92 per share. | 13 Feb 2026 | 35,870 | 1,006,709 (0%) | 0% | 43.9 | 1,575,410 | - |
| Mr. Christopher J. Senner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 43.67 per share. | 13 Feb 2026 | 30,617 | 976,092 (0%) | 0% | 43.7 | 1,337,044 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 548,073 | 1,964,765 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.23 per share. | 15 Jan 2026 | 139,524 | 1,825,241 (0%) | 0% | 45.2 | 6,310,671 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 149,474 | 1,117,316 (0%) | 0% | 0 | Common Stock | |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.23 per share. | 15 Jan 2026 | 40,459 | 1,076,857 (0%) | 0% | 45.2 | 1,829,961 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 139,508 | 513,537 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.23 per share. | 15 Jan 2026 | 32,332 | 481,205 (0%) | 0% | 45.2 | 1,462,376 | Common Stock |
| Dr. Dana T. Aftab, PhD | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 119,578 | 760,356 (0%) | 0% | 0 | Common Stock | |
| Dr. Dana T. Aftab, PhD | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.23 per share. | 15 Jan 2026 | 27,254 | 733,102 (0%) | 0% | 45.2 | 1,232,698 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 548,073 | 1,964,765 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.23 per share. | 15 Jan 2026 | 139,524 | 1,825,241 (0%) | 0% | 45.2 | 6,310,671 | - |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 149,474 | 1,117,316 (0%) | 0% | 0 | - | |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.23 per share. | 15 Jan 2026 | 40,459 | 1,076,857 (0%) | 0% | 45.2 | 1,829,961 | - |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 139,508 | 513,537 (0%) | 0% | 0 | - | |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.23 per share. | 15 Jan 2026 | 32,332 | 481,205 (0%) | 0% | 45.2 | 1,462,376 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 548,073 | 1,964,765 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.23 per share. | 15 Jan 2026 | 139,524 | 1,825,241 (0%) | 0% | 45.2 | 6,310,671 | - |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 149,474 | 1,117,316 (0%) | 0% | 0 | - | |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.23 per share. | 15 Jan 2026 | 40,459 | 1,076,857 (0%) | 0% | 45.2 | 1,829,961 | - |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 139,508 | 513,537 (0%) | 0% | 0 | - | |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.23 per share. | 15 Jan 2026 | 32,332 | 481,205 (0%) | 0% | 45.2 | 1,462,376 | - |
| Dr. Brenda Hefti, J.D.,PhD | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2025 | 30,170 | 120,611 (0%) | 0% | 0 | Common Stock | |
| Dr. Dana T. Aftab, PhD | EVP, Research and Development | Gift of securities by or to the insider at price $ 0.00 per share. | 21 Nov 2025 | 24,000 | 640,778 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 41.77 per share. | 20 Nov 2025 | 10,648 | 0 (0%) | 0% | 41.8 | 444,767 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 42.58 per share. | 20 Nov 2025 | 28,043 | 374,029 (0%) | 0% | 42.6 | 1,194,071 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 41.93 per share. | 20 Nov 2025 | 23,539 | 0 (0%) | 0% | 41.9 | 986,990 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 42.11 per share. | 20 Nov 2025 | 10,000 | 402,072 (0%) | 0% | 42.1 | 421,100 | Common Stock |
| Mr. Bob Oliver | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Nov 2025 | 1,044 | 42,282 (0%) | 0% | 0 | Common Stock | |
| Dr. Stelios Papadopoulos,PhD | Director | Sale of securities on an exchange or to another person at price $ 43.55 per share. | 12 Nov 2025 | 100,000 | 1,189,228 (0%) | 0% | 43.6 | 4,355,000 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Nov 2025 | 101,548 | 1,416,692 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Nov 2025 | 80,000 | 1,714,404 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Nov 2025 | 101,548 | 1,794,404 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Nov 2025 | 160,000 | 1,692,856 (0%) | 0% | 0 | Common Stock | |
| Dr. Mary C. Beckerle, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.24 per share. | 11 Nov 2025 | 5,784 | 46,002 (0%) | 0% | 23.2 | 134,420 | Common Stock |
| Dr. Mary C. Beckerle, PhD | Director | 11 Nov 2025 | 5,784 | 16,710 | - | - | Option (right to buy) | ||
| Dr. Mary C. Beckerle, PhD | Director | Sale of securities on an exchange or to another person at price $ 41.90 per share. | 11 Nov 2025 | 18,838 | 21,380 (0%) | 0% | 41.9 | 789,312 | Common Stock |
| Dr. Mary C. Beckerle, PhD | Director | Sale of securities on an exchange or to another person at price $ 42.03 per share. | 11 Nov 2025 | 5,784 | 40,218 (0%) | 0% | 42.0 | 243,102 | Common Stock |
| Dr. Dana T. Aftab, PhD | EVP, Research and Development | Sale of securities on an exchange or to another person at price $ 42.50 per share. | 11 Nov 2025 | 48,383 | 664,778 (0%) | 0% | 42.5 | 2,056,278 | Common Stock |
| Dr. Dana T. Aftab, PhD | EVP, Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2025 | 50,673 | 713,161 (0%) | 0% | 0 | Common Stock | |
| Mr. Jack L. Wyszomierski, M.S. | Director | Sale of securities on an exchange or to another person at price $ 43.09 per share. | 03 Jun 2025 | 7,535 | 358,882 (0%) | 0% | 43.1 | 324,683 | Common Stock |
| Dr. Sue Gail Eckhardt, M.D. | Director | Sale of securities on an exchange or to another person at price $ 43.75 per share. | 02 Jun 2025 | 4 | 21,380 (0%) | 0% | 43.8 | 175 | Common Stock |
| Dr. Sue Gail Eckhardt, M.D. | Director | Sale of securities on an exchange or to another person at price $ 42.74 per share. | 02 Jun 2025 | 18,834 | 21,384 (0%) | 0% | 42.7 | 804,965 | Common Stock |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 178,832 (0%) | 0% | 0 | Common Stock | |
| Mr. Jack L. Wyszomierski, M.S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 366,417 (0%) | 0% | 0 | Common Stock | |
| Dr. Stelios Papadopoulos,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 1,289,228 (0%) | 0% | 0 | Common Stock | |
| Dr. Mary C. Beckerle, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 40,218 (0%) | 0% | 0 | Common Stock | |
| Dr. Maria C. Freire, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 100,819 (0%) | 0% | 0 | Common Stock | |
| Ms. Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 20,590 (0%) | 0% | 0 | Common Stock | |
| Mr. Bob Oliver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 43,326 (0%) | 0% | 0 | Common Stock | |
| Mr. Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 42,282 (0%) | 0% | 0 | Common Stock | |
| Dr. Sue Gail Eckhardt, M.D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 40,218 (0%) | 0% | 0 | Common Stock | |
| Mr. Tomas J. Heyman | Director | Sale of securities on an exchange or to another person at price $ 44.29 per share. | 21 May 2025 | 4,544 | 32,470 (0%) | 0% | 44.3 | 201,254 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 44.06 per share. | 20 May 2025 | 34,387 | 412,072 (0%) | 0% | 44.1 | 1,515,091 | Common Stock |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Sale of securities on an exchange or to another person at price $ 45.99 per share. | 16 May 2025 | 20,634 | 169,020 (0%) | 0% | 46.0 | 948,958 | Common Stock |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | 16 May 2025 | 20,634 | 0 | - | - | Option (right to buy) | ||
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 16 May 2025 | 20,634 | 189,654 (0%) | 0% | 19.8 | 407,934 | Common Stock |
| Dr. Stelios Papadopoulos,PhD | Director | 15 May 2025 | 20,634 | 0 | - | - | Option (right to buy) | ||
| Dr. Stelios Papadopoulos,PhD | Director | 15 May 2025 | 15,874 | 0 | - | - | Option (right to buy) | ||
| Dr. Stelios Papadopoulos,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 15 May 2025 | 20,634 | 1,300,050 (0%) | 0% | 19.8 | 407,934 | Common Stock |
| Dr. Stelios Papadopoulos,PhD | Director | Sale of securities on an exchange or to another person at price $ 44.35 per share. | 15 May 2025 | 20,634 | 1,279,416 (0%) | 0% | 44.4 | 915,118 | Common Stock |
| Dr. Stelios Papadopoulos,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.50 per share. | 15 May 2025 | 15,874 | 1,295,290 (0%) | 0% | 20.5 | 325,417 | Common Stock |
| Dr. Stelios Papadopoulos,PhD | Director | Sale of securities on an exchange or to another person at price $ 44.35 per share. | 15 May 2025 | 15,874 | 1,279,416 (0%) | 0% | 44.4 | 704,012 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 46.18 per share. | 15 May 2025 | 25,000 | 693,396 (0%) | 0% | 46.2 | 1,154,500 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.65 per share. | 15 May 2025 | 34,035 | 718,396 (0%) | 0% | 44.7 | 1,519,663 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | 15 May 2025 | 100,000 | 0 | - | - | Option (right to buy) | ||
| Mr. Christopher J. Senner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 46.00 per share. | 15 May 2025 | 100,000 | 967,842 (0%) | 0% | 46 | 4,600,000 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.80 per share. | 15 May 2025 | 100,000 | 1,067,842 (0%) | 0% | 18.8 | 1,880,000 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.65 per share. | 15 May 2025 | 41,422 | 967,842 (0%) | 0% | 44.6 | 1,849,492 | Common Stock |
| Dr. Amy C. Peterson, M.D. | EVP Prod Dev & Med Aff & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.65 per share. | 15 May 2025 | 8,303 | 498,169 (0%) | 0% | 44.7 | 370,729 | Common Stock |
| Dr. Amy C. Peterson, M.D. | EVP Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.75 per share. | 15 May 2025 | 40,000 | 538,169 (0%) | 0% | 21.8 | 870,000 | Common Stock |
| Dr. Amy C. Peterson, M.D. | EVP Prod Dev & Med Aff & CMO | Sale of securities on an exchange or to another person at price $ 45.47 per share. | 15 May 2025 | 72,776 | 465,393 (0%) | 0% | 45.5 | 3,309,125 | Common Stock |
| Dr. Amy C. Peterson, M.D. | EVP Prod Dev & Med Aff & CMO | 15 May 2025 | 40,000 | 120,000 | - | - | Option (right to buy) | ||
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.65 per share. | 15 May 2025 | 30,693 | 662,488 (0%) | 0% | 44.6 | 1,370,442 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 May 2025 | 87,871 | 1,518,240 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | 14 May 2025 | 308,365 | 0 | - | - | Option (right to buy) | ||
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.65 per share. | 14 May 2025 | 104,769 | 1,606,111 (0%) | 0% | 44.7 | 4,677,936 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.65 per share. | 14 May 2025 | 220,494 | 1,710,880 (0%) | 0% | 44.6 | 9,845,057 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.80 per share. | 14 May 2025 | 308,365 | 1,931,374 (0%) | 0% | 18.8 | 5,797,262 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 14 May 2025 | 87,871 | 1,852,856 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.65 per share. | 14 May 2025 | 34,705 | 456,459 (0%) | 0% | 44.6 | 1,549,578 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | 14 May 2025 | 116,383 | 0 | - | - | Option (right to buy) | ||
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 48.05 per share. | 14 May 2025 | 116,383 | 446,459 (0%) | 0% | 48.0 | 5,592,203 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.80 per share. | 14 May 2025 | 116,383 | 562,842 (0%) | 0% | 18.8 | 2,188,000 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 46.95 per share. | 14 May 2025 | 10,000 | 446,459 (0%) | 0% | 47.0 | 469,500 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 42.68 per share. | 14 May 2025 | 10,000 | 491,164 (0%) | 0% | 42.7 | 426,800 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Sale of securities on an exchange or to another person at price $ 39.00 per share. | 01 May 2025 | 1,508 | 693,181 (0%) | 0% | 39 | 58,812 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 589,719 | 1,623,009 (0%) | 0% | 0 | Common Stock | |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 154,070 | 751,678 (0%) | 0% | 0 | Common Stock | |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 170,009 | 1,009,264 (0%) | 0% | 0 | Common Stock | |
| Dr. Amy C. Peterson, M.D. | EVP Prod Dev & Med Aff & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 159,383 | 506,472 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 159,383 | 500,411 (0%) | 0% | 0 | Common Stock | |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 132,819 | 693,936 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 38.80 per share. | 03 Mar 2025 | 10,000 | 341,028 (0%) | 0% | 38.8 | 388,000 | Common Stock |
| Mr. Jack L. Wyszomierski, M.S. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.50 per share. | 28 Feb 2025 | 15,874 | 365,373 (0%) | 0% | 20.5 | 325,417 | Common Stock |
| Mr. Jack L. Wyszomierski, M.S. | Director | Sale of securities on an exchange or to another person at price $ 37.80 per share. | 28 Feb 2025 | 8,768 | 356,605 (0%) | 0% | 37.8 | 331,430 | Common Stock |
| Mr. Jack L. Wyszomierski, M.S. | Director | 28 Feb 2025 | 15,874 | 0 | - | - | Option (right to buy) | ||
| Ms. Julie Anne Smith | Director | 27 Feb 2025 | 23,347 | 19,294 | - | - | Option (right to buy) | ||
| Ms. Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.50 per share. | 27 Feb 2025 | 31,167 | 41,945 (0%) | 0% | 20.5 | 638,924 | Common Stock |
| Ms. Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 27 Feb 2025 | 23,347 | 65,292 (0%) | 0% | 19.8 | 461,570 | Common Stock |
| Ms. Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 37.62 per share. | 27 Feb 2025 | 19,294 | 10,778 (0%) | 0% | 37.6 | 725,840 | Common Stock |
| Ms. Julie Anne Smith | Director | 27 Feb 2025 | 19,294 | 0 | - | - | Option (right to buy) | ||
| Ms. Julie Anne Smith | Director | 27 Feb 2025 | 31,167 | 0 | - | - | Option (right to buy) | ||
| Ms. Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 38.13 per share. | 27 Feb 2025 | 54,514 | 10,778 (0%) | 0% | 38.1 | 2,078,619 | Common Stock |
| Ms. Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 27 Feb 2025 | 19,294 | 30,072 (0%) | 0% | 19.8 | 381,442 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 184,909 | 1,033,290 (0%) | 0% | 0 | Common Stock | |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 52,192 | 597,608 (0%) | 0% | 0 | Common Stock | |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 59,648 | 839,255 (0%) | 0% | 0 | Common Stock | |
| Dr. Amy C. Peterson, M.D. | EVP Prod Dev & Med Aff & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 52,192 | 347,089 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 47,718 | 351,028 (0%) | 0% | 0 | Common Stock | |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 49,209 | 561,117 (0%) | 0% | 0 | Common Stock | |
| Mr. Bob Oliver | Director | 25 Feb 2025 | 15,147 | 21,206 | - | - | Option (right to buy) | ||
| Mr. Bob Oliver | Director | Sale of securities on an exchange or to another person at price $ 37.25 per share. | 25 Feb 2025 | 18,647 | 33,514 (0%) | 0% | 37.3 | 694,601 | Common Stock |
| Mr. Bob Oliver | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.28 per share. | 25 Feb 2025 | 15,147 | 52,161 (0%) | 0% | 19.3 | 292,034 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Feb 2025 | 177,985 | 848,381 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Feb 2025 | 177,985 | 1,764,985 (0%) | 0% | 0 | Common Stock | |
| Mr. Christopher J. Senner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 36.14 per share. | 24 Feb 2025 | 29,314 | 779,607 (0%) | 0% | 36.1 | 1,059,408 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.80 per share. | 24 Feb 2025 | 29,314 | 808,921 (0%) | 0% | 18.8 | 551,103 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | 24 Feb 2025 | 29,314 | 100,000 | - | - | Option (right to buy) | ||
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 36.98 per share. | 24 Feb 2025 | 52,636 | 303,310 (0%) | 0% | 37.0 | 1,946,479 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Sale of securities on an exchange or to another person at price $ 36.75 per share. | 24 Feb 2025 | 26,987 | 511,908 (0%) | 0% | 36.7 | 991,772 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.00 per share. | 15 Feb 2025 | 63,570 | 1,026,366 (0%) | 0% | 35 | 2,224,950 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.00 per share. | 15 Feb 2025 | 18,134 | 545,416 (0%) | 0% | 35 | 634,690 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.00 per share. | 15 Feb 2025 | 21,591 | 779,607 (0%) | 0% | 35 | 755,685 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.00 per share. | 15 Feb 2025 | 18,906 | 355,946 (0%) | 0% | 35 | 661,710 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.00 per share. | 15 Feb 2025 | 16,053 | 551,590 (0%) | 0% | 35 | 561,855 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.00 per share. | 15 Feb 2025 | 12,695 | 538,895 (0%) | 0% | 35 | 444,325 | Common Stock |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.50 per share. | 14 Feb 2025 | 15,874 | 184,894 (0%) | 0% | 20.5 | 325,417 | Common Stock |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Sale of securities on an exchange or to another person at price $ 34.74 per share. | 14 Feb 2025 | 15,874 | 169,020 (0%) | 0% | 34.7 | 551,463 | Common Stock |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | 14 Feb 2025 | 15,874 | 0 | - | - | Option (right to buy) | ||
| Dr. Mary C. Beckerle, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.24 per share. | 14 Feb 2025 | 8,354 | 42,616 (0%) | 0% | 23.2 | 194,147 | Common Stock |
| Dr. Mary C. Beckerle, PhD | Director | 14 Feb 2025 | 8,354 | 22,494 | - | - | Option (right to buy) | ||
| Dr. Mary C. Beckerle, PhD | Director | Sale of securities on an exchange or to another person at price $ 34.90 per share. | 14 Feb 2025 | 3,856 | 30,406 (0%) | 0% | 34.9 | 134,574 | Common Stock |
| Dr. Mary C. Beckerle, PhD | Director | Sale of securities on an exchange or to another person at price $ 34.87 per share. | 14 Feb 2025 | 8,354 | 34,262 (0%) | 0% | 34.9 | 291,304 | Common Stock |
| Dr. Maria C. Freire, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.50 per share. | 14 Feb 2025 | 15,874 | 106,881 (0%) | 0% | 20.5 | 325,417 | Common Stock |
| Dr. Maria C. Freire, PhD | Director | 14 Feb 2025 | 28,240 | 0 | - | - | Option (right to buy) | ||
| Dr. Maria C. Freire, PhD | Director | 14 Feb 2025 | 15,874 | 0 | - | - | Option (right to buy) | ||
| Dr. Maria C. Freire, PhD | Director | Sale of securities on an exchange or to another person at price $ 34.94 per share. | 14 Feb 2025 | 44,114 | 91,007 (0%) | 0% | 34.9 | 1,541,343 | Common Stock |
| Dr. Maria C. Freire, PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.10 per share. | 14 Feb 2025 | 28,240 | 135,121 (0%) | 0% | 22.1 | 624,104 | Common Stock |
| Dr. Sue Gail Eckhardt, M.D. | Director | Sale of securities on an exchange or to another person at price $ 35.04 per share. | 14 Feb 2025 | 3,856 | 30,406 (0%) | 0% | 35.0 | 135,114 | Common Stock |
| Dr. Sue Gail Eckhardt, M.D. | Director | Sale of securities on an exchange or to another person at price $ 35.01 per share. | 14 Feb 2025 | 7,712 | 34,262 (0%) | 0% | 35.0 | 269,997 | Common Stock |
| Dr. Sue Gail Eckhardt, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.24 per share. | 14 Feb 2025 | 7,712 | 41,974 (0%) | 0% | 23.2 | 179,227 | Common Stock |
| Dr. Sue Gail Eckhardt, M.D. | Director | 14 Feb 2025 | 7,712 | 23,136 | - | - | Option (right to buy) | ||
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.27 per share. | 16 Jan 2025 | 120,244 | 1,089,936 (0%) | 0% | 37.3 | 4,481,494 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2025 | 473,226 | 1,210,180 (0%) | 0% | 0 | Common Stock | |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2025 | 118,780 | 589,839 (0%) | 0% | 0 | Common Stock | |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.27 per share. | 16 Jan 2025 | 26,289 | 563,550 (0%) | 0% | 37.3 | 979,791 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.27 per share. | 16 Jan 2025 | 35,949 | 801,198 (0%) | 0% | 37.3 | 1,339,819 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2025 | 132,973 | 837,147 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2025 | 123,750 | 402,415 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.27 per share. | 16 Jan 2025 | 27,563 | 374,852 (0%) | 0% | 37.3 | 1,027,273 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2025 | 104,106 | 590,213 (0%) | 0% | 0 | Common Stock | |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.27 per share. | 16 Jan 2025 | 22,570 | 567,643 (0%) | 0% | 37.3 | 841,184 | Common Stock |
| Michael M. Morrissey | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Dec 2024 | 179,788 | 736,954 (0%) | 0% | 0 | Common Stock | |
| M. Michael Morrissey | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Dec 2024 | 179,788 | 1,587,000 (0%) | 0% | 0 | Common Stock | |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.80 per share. | 27 Nov 2024 | 129,314 | 644,967 (0%) | 0% | 18.8 | 2,431,103 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | 27 Nov 2024 | 129,314 | 0 | - | - | Option (right to buy) | ||
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Nov 2024 | 15,000 | 471,059 (0%) | 0% | 0 | Common Stock | |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 36.67 per share. | 27 Nov 2024 | 60,000 | 486,059 (0%) | 0% | 36.7 | 2,200,200 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.93 per share. | 27 Nov 2024 | 98,908 | 546,059 (0%) | 0% | 35.9 | 3,553,764 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 35.27 per share. | 22 Nov 2024 | 10,000 | 278,665 (0%) | 0% | 35.3 | 352,700 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.05 per share. | 15 Nov 2024 | 47,642 | 916,742 (0%) | 0% | 35.0 | 1,669,852 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.05 per share. | 15 Nov 2024 | 14,672 | 515,653 (0%) | 0% | 35.1 | 514,254 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.05 per share. | 15 Nov 2024 | 17,506 | 704,174 (0%) | 0% | 35.0 | 613,585 | Common Stock |
| Dr. Amy C. Peterson, M.D. | EVP Prod Dev & Med Aff & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.05 per share. | 15 Nov 2024 | 27,224 | 294,897 (0%) | 0% | 35.0 | 954,201 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 34.31 per share. | 15 Nov 2024 | 22,207 | 308,046 (0%) | 0% | 34.3 | 761,922 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.05 per share. | 15 Nov 2024 | 14,672 | 330,253 (0%) | 0% | 35.1 | 514,254 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 34.41 per share. | 15 Nov 2024 | 19,381 | 288,665 (0%) | 0% | 34.4 | 666,900 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.05 per share. | 15 Nov 2024 | 12,838 | 486,107 (0%) | 0% | 35.1 | 449,972 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 05 Nov 2024 | 96,986 | 498,945 (0%) | 0% | 35 | 3,394,510 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | 05 Nov 2024 | 96,986 | 0 | - | - | Option (right to buy) | ||
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.80 per share. | 05 Nov 2024 | 96,986 | 595,931 (0%) | 0% | 18.8 | 1,823,337 | Common Stock |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Sale of securities on an exchange or to another person at price $ 34.00 per share. | 01 Nov 2024 | 30,000 | 169,020 (0%) | 0% | 34 | 1,020,000 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 34.13 per share. | 01 Nov 2024 | 50,000 | 530,325 (0%) | 0% | 34.1 | 1,706,500 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Oct 2024 | 46,000 | 1,407,212 (0%) | 0% | 0 | Common Stock | |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Sale of securities on an exchange or to another person at price $ 31.40 per share. | 30 Oct 2024 | 1,162 | 498,945 (0%) | 0% | 31.4 | 36,487 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 28.39 per share. | 28 Oct 2024 | 25,000 | 580,325 (0%) | 0% | 28.4 | 709,750 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.41 per share. | 02 Oct 2024 | 100,000 | 441,036 (0%) | 0% | 24.4 | 2,441,000 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.50 per share. | 02 Oct 2024 | 96,111 | 344,925 (0%) | 0% | 26.5 | 2,546,942 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | 02 Oct 2024 | 100,000 | 0 | - | - | Option (right to buy) | ||
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.41 per share. | 01 Oct 2024 | 480,000 | 1,444,384 (0%) | 0% | 24.4 | 11,716,800 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.30 per share. | 01 Oct 2024 | 463,702 | 980,682 (0%) | 0% | 26.3 | 12,195,363 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | 01 Oct 2024 | 480,000 | 0 | - | - | Option (right to buy) | ||
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Oct 2024 | 16,298 | 1,453,212 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Oct 2024 | 16,298 | 964,384 (0%) | 0% | 0 | Common Stock | |
| Mr. Jeffrey J. Hessekiel | EVP & General Counsel | Sale of securities on an exchange or to another person at price $ 26.38 per share. | 23 Sep 2024 | 25,000 | 605,325 (0%) | 0% | 26.4 | 659,500 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | 26 Aug 2024 | 20,000 | 0 | - | - | Option (right to buy) | ||
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Sale of securities on an exchange or to another person at price $ 25.79 per share. | 26 Aug 2024 | 20,000 | 630,325 (0%) | 0% | 25.8 | 515,800 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.41 per share. | 26 Aug 2024 | 20,000 | 650,325 (0%) | 0% | 24.4 | 488,200 | Common Stock |
| Dr. Maria C. Freire, PhD | Director | Sale of securities on an exchange or to another person at price $ 26.56 per share. | 14 Aug 2024 | 8,250 | 91,007 (0%) | 0% | 26.6 | 219,120 | Common Stock |
| Ms. Julie Anne Smith | Director | Other type of transaction at price $ 0.00 per share. | 13 Aug 2024 | 4,682 | 10,778 (0%) | 0% | 0 | Common Stock | |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Sale of securities on an exchange or to another person at price $ 27.06 per share. | 12 Aug 2024 | 20,883 | 500,107 (0%) | 0% | 27.1 | 565,094 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.41 per share. | 09 Aug 2024 | 125,000 | 846,680 (0%) | 0% | 24.4 | 3,051,250 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | 09 Aug 2024 | 125,000 | 0 | - | - | Option (right to buy) | ||
| Mr. Christopher J. Senner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 27.19 per share. | 09 Aug 2024 | 125,000 | 721,680 (0%) | 0% | 27.2 | 3,398,750 | Common Stock |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Sale of securities on an exchange or to another person at price $ 26.89 per share. | 08 Aug 2024 | 33,725 | 199,020 (0%) | 0% | 26.9 | 906,865 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.41 per share. | 07 Aug 2024 | 80,000 | 710,325 (0%) | 0% | 24.4 | 1,952,800 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | 07 Aug 2024 | 80,000 | 20,000 | - | - | Option (right to buy) | ||
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Sale of securities on an exchange or to another person at price $ 25.97 per share. | 07 Aug 2024 | 80,000 | 630,325 (0%) | 0% | 26.0 | 2,077,600 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 25.50 per share. | 07 Aug 2024 | 14,000 | 341,036 (0%) | 0% | 25.5 | 357,000 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.41 per share. | 07 Aug 2024 | 95,000 | 615,990 (0%) | 0% | 24.4 | 2,318,950 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | 07 Aug 2024 | 95,000 | 0 | - | - | Option (right to buy) | ||
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 07 Aug 2024 | 95,000 | 520,990 (0%) | 0% | 25 | 2,375,000 | Common Stock |
| Mr. Jack L. Wyszomierski, M.S. | Director | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 04 Jun 2024 | 8,287 | 349,499 (0%) | 0% | 22 | 182,314 | Common Stock |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 232,745 (0%) | 0% | 0 | Common Stock | |
| Mr. Jack L. Wyszomierski, M.S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 357,786 (0%) | 0% | 0 | Common Stock | |
| Dr. Stelios Papadopoulos,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 1,279,416 (0%) | 0% | 0 | Common Stock | |
| Dr. Mary C. Beckerle, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 34,262 (0%) | 0% | 0 | Common Stock | |
| Dr. Maria C. Freire, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 99,257 (0%) | 0% | 0 | Common Stock | |
| Ms. Julie Anne Smith | Director | 31 May 2024 | 20,030 | 20,030 | - | - | Option (right to buy) | ||
| Ms. Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 10,015 | 15,460 (0%) | 0% | 0 | Common Stock | |
| Mr. Bob Oliver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 37,014 (0%) | 0% | 0 | Common Stock | |
| Mr. Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 37,014 (0%) | 0% | 0 | Common Stock | |
| Dr. Sue Gail Eckhardt, M.D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 34,262 (0%) | 0% | 0 | Common Stock | |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | 21 May 2024 | 11,686 | 0 | - | - | Option (right to buy) | ||
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Sale of securities on an exchange or to another person at price $ 20.96 per share. | 21 May 2024 | 11,686 | 213,907 (0%) | 0% | 21.0 | 244,939 | Common Stock |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.57 per share. | 21 May 2024 | 11,686 | 225,593 (0%) | 0% | 19.6 | 228,695 | Common Stock |
| Ms. Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 21.12 per share. | 21 May 2024 | 27,280 | 5,445 (0%) | 0% | 21.1 | 576,154 | Common Stock |
| Dr. Stelios Papadopoulos,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.57 per share. | 20 May 2024 | 11,686 | 1,272,015 (0%) | 0% | 19.6 | 228,695 | Common Stock |
| Dr. Stelios Papadopoulos,PhD | Director | 20 May 2024 | 11,686 | 0 | - | - | Option (right to buy) | ||
| Dr. Stelios Papadopoulos,PhD | Director | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 20 May 2024 | 11,437 | 1,260,578 (0%) | 0% | 21 | 240,177 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 34,262 | 1,004,065 (0%) | 0% | 21.0 | 719,159 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 39,681 | 964,384 (0%) | 0% | 21.0 | 832,904 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 10,101 | 630,325 (0%) | 0% | 21.0 | 212,020 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 7,240 | 649,026 (0%) | 0% | 21.0 | 151,968 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 8,600 | 640,426 (0%) | 0% | 21.0 | 180,514 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 11,478 | 721,680 (0%) | 0% | 21.0 | 240,923 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 10,211 | 733,158 (0%) | 0% | 21.0 | 214,329 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 8,621 | 743,369 (0%) | 0% | 21.0 | 180,955 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 8,960 | 365,137 (0%) | 0% | 21.0 | 188,070 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 10,101 | 355,036 (0%) | 0% | 21.0 | 212,020 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 4,435 | 381,645 (0%) | 0% | 21.0 | 93,091 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 7,548 | 374,097 (0%) | 0% | 21.0 | 158,433 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 7,538 | 529,648 (0%) | 0% | 21.0 | 158,223 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 8,658 | 520,990 (0%) | 0% | 21.0 | 181,731 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.99 per share. | 15 May 2024 | 6,409 | 537,186 (0%) | 0% | 21.0 | 134,525 | Common Stock |
| Mr. Jack L. Wyszomierski, M.S. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.57 per share. | 13 May 2024 | 11,686 | 349,871 (0%) | 0% | 19.6 | 228,695 | Common Stock |
| Mr. Jack L. Wyszomierski, M.S. | Director | Sale of securities on an exchange or to another person at price $ 21.37 per share. | 13 May 2024 | 10,923 | 338,948 (0%) | 0% | 21.4 | 233,425 | Common Stock |
| Mr. Jack L. Wyszomierski, M.S. | Director | 13 May 2024 | 11,686 | 0 | - | - | Option (right to buy) | ||
| Dr. Alan M. Garber, M.D.,PhD | Director | 21 Mar 2024 | 23,491 | 0 | - | - | Option (right to buy) | ||
| Dr. Alan M. Garber, M.D.,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.57 per share. | 21 Mar 2024 | 23,491 | 54,908 (0%) | 0% | 19.6 | 459,719 | Common Stock |
| Dr. Alan M. Garber, M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 24.01 per share. | 21 Mar 2024 | 19,205 | 35,703 (0%) | 0% | 24.0 | 461,112 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 82,121 | 751,990 (0%) | 0% | 0 | Common Stock | |
| Dr. Amy C. Peterson, M.D. | EVP Prod Dev & Med Aff & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 82,121 | 322,121 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 63,350 | 431,886 (0%) | 0% | 0 | Common Stock | |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 63,350 | 542,381 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 241,670 | 1,038,327 (0%) | 0% | 0 | Common Stock | |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 63,350 | 655,052 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 21.45 per share. | 23 Feb 2024 | 47,020 | 384,866 (0%) | 0% | 21.5 | 1,008,579 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.39 per share. | 15 Feb 2024 | 10,630 | 479,031 (0%) | 0% | 20.4 | 216,746 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.86 per share. | 11 Jan 2024 | 13,061 | 591,702 (0%) | 0% | 22.9 | 298,574 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.86 per share. | 11 Jan 2024 | 13,613 | 368,536 (0%) | 0% | 22.9 | 311,193 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2024 | 250,374 | 860,374 (0%) | 0% | 0 | Common Stock | |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2024 | 80,186 | 691,731 (0%) | 0% | 0 | Common Stock | |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2024 | 71,418 | 604,763 (0%) | 0% | 0 | Common Stock | |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.86 per share. | 11 Jan 2024 | 11,606 | 489,661 (0%) | 0% | 22.9 | 265,313 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2024 | 63,224 | 501,267 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2024 | 74,462 | 382,149 (0%) | 0% | 0 | Common Stock | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.86 per share. | 11 Jan 2024 | 63,717 | 796,657 (0%) | 0% | 22.9 | 1,456,571 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.86 per share. | 11 Jan 2024 | 21,862 | 669,869 (0%) | 0% | 22.9 | 499,765 | Common Stock |
| Dr. Sue Gail Eckhardt, M.D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 15,424 | 15,424 (0%) | 0% | 0 | Common Stock | |
| Dr. Mary C. Beckerle, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 15,424 | 15,424 (0%) | 0% | 0 | Common Stock | |
| Dr. Mary C. Beckerle, PhD | Director | 05 Jan 2024 | 30,848 | 30,848 | - | - | Option (right to buy) | ||
| Dr. Sue Gail Eckhardt, M.D. | Director | 05 Jan 2024 | 30,848 | 30,848 | - | - | Option (right to buy) | ||
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Sale of securities on an exchange or to another person at price $ 23.01 per share. | 13 Dec 2023 | 25,000 | 533,345 (0%) | 0% | 23.0 | 575,250 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | 12 Dec 2023 | 50,000 | 0 | - | - | Option (right to buy) | ||
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 23.35 per share. | 12 Dec 2023 | 50,000 | 307,687 (0%) | 0% | 23.4 | 1,167,500 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.29 per share. | 12 Dec 2023 | 50,000 | 357,687 (0%) | 0% | 16.3 | 814,500 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 12 Dec 2023 | 14,149 | 307,687 (0%) | 0% | 22.5 | 318,353 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Sale of securities on an exchange or to another person at price $ 22.01 per share. | 30 Nov 2023 | 25,000 | 583,345 (0%) | 0% | 22.0 | 550,250 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Sale of securities on an exchange or to another person at price $ 22.06 per share. | 30 Nov 2023 | 25,000 | 558,345 (0%) | 0% | 22.1 | 551,500 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Nov 2023 | 19,020 | 1,436,914 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Nov 2023 | 19,020 | 1,436,914 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Nov 2023 | 116,893 | 610,000 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Nov 2023 | 116,893 | 1,455,934 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Nov 2023 | 116,893 | 610,000 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Nov 2023 | 116,893 | 1,455,934 (0%) | 0% | 0 | - | |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 06 Sep 2023 | 14,354 | 608,345 (0%) | 0% | 22.3 | 319,664 | - |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2023 | 57,900 | 622,699 (0%) | 0% | 0 | - | |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2023 | 50,660 | 450,603 (0%) | 0% | 0 | - | |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 06 Sep 2023 | 12,560 | 438,043 (0%) | 0% | 22.3 | 279,711 | - |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2023 | 65,135 | 628,692 (0%) | 0% | 0 | - | |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 06 Sep 2023 | 17,147 | 611,545 (0%) | 0% | 22.3 | 381,864 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2023 | 188,005 | 773,501 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 06 Sep 2023 | 46,608 | 726,893 (0%) | 0% | 22.3 | 1,037,960 | - |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2023 | 57,900 | 336,190 (0%) | 0% | 0 | - | |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 06 Sep 2023 | 14,354 | 321,836 (0%) | 0% | 22.3 | 319,664 | - |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2023 | 50,660 | 450,603 (0%) | 0% | 0 | - | |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 06 Sep 2023 | 12,560 | 438,043 (0%) | 0% | 22.3 | 279,711 | - |
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2023 | 65,135 | 628,692 (0%) | 0% | 0 | - | |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 06 Sep 2023 | 17,147 | 611,545 (0%) | 0% | 22.3 | 381,864 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2023 | 188,005 | 773,501 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 06 Sep 2023 | 46,608 | 726,893 (0%) | 0% | 22.3 | 1,037,960 | - |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2023 | 57,900 | 336,190 (0%) | 0% | 0 | - | |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 06 Sep 2023 | 14,354 | 321,836 (0%) | 0% | 22.3 | 319,664 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Aug 2023 | 56,221 | 585,496 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Aug 2023 | 56,221 | 1,396,541 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Aug 2023 | 57,500 | 1,339,041 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Aug 2023 | 56,221 | 585,496 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Aug 2023 | 56,221 | 1,396,541 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Aug 2023 | 57,500 | 1,339,041 (0%) | 0% | 0 | - | |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Sale of securities on an exchange or to another person at price $ 22.47 per share. | 30 Aug 2023 | 4,600 | 399,943 (0%) | 0% | 22.5 | 103,362 | - |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Sale of securities on an exchange or to another person at price $ 22.47 per share. | 30 Aug 2023 | 4,600 | 399,943 (0%) | 0% | 22.5 | 103,362 | - |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.31 per share. | 28 Aug 2023 | 360,000 | 945,496 (0%) | 0% | 15.3 | 5,511,600 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.18 per share. | 28 Aug 2023 | 303,779 | 641,717 (0%) | 0% | 22.2 | 6,737,818 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | 28 Aug 2023 | 360,000 | 0 | - | - | Option (right to buy) | ||
| Dr. Amy C. Peterson, M.D. | EVP Prod Dev & Med Aff & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Aug 2023 | 240,000 | 240,000 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.51 per share. | 15 Aug 2023 | 23,304 | 585,496 (0%) | 0% | 21.5 | 501,269 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.51 per share. | 15 Aug 2023 | 7,177 | 564,799 (0%) | 0% | 21.5 | 154,377 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.51 per share. | 15 Aug 2023 | 8,074 | 563,557 (0%) | 0% | 21.5 | 173,672 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.51 per share. | 15 Aug 2023 | 7,177 | 278,290 (0%) | 0% | 21.5 | 154,377 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.51 per share. | 15 Aug 2023 | 6,280 | 404,543 (0%) | 0% | 21.5 | 135,083 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 20.51 per share. | 03 Aug 2023 | 60,000 | 571,631 (0%) | 0% | 20.5 | 1,230,600 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | 03 Aug 2023 | 60,000 | 0 | - | - | Option (right to buy) | ||
| Mr. Christopher J. Senner | EVP and CFO | 03 Aug 2023 | 60,000 | 60,000 | - | - | Option (right to buy) | ||
| Mr. Christopher J. Senner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 20.68 per share. | 03 Aug 2023 | 60,000 | 571,631 (0%) | 0% | 20.7 | 1,240,800 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.74 per share. | 03 Aug 2023 | 60,000 | 631,631 (0%) | 0% | 14.7 | 884,400 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.74 per share. | 03 Aug 2023 | 60,000 | 631,631 (0%) | 0% | 14.7 | 884,400 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Sale of securities on an exchange or to another person at price $ 20.67 per share. | 03 Aug 2023 | 30,553 | 285,467 (0%) | 0% | 20.7 | 631,531 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.74 per share. | 01 Aug 2023 | 55,710 | 627,686 (0%) | 0% | 14.7 | 821,165 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | 01 Aug 2023 | 55,710 | 0 | - | - | Option (right to buy) | ||
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Sale of securities on an exchange or to another person at price $ 19.63 per share. | 01 Aug 2023 | 55,710 | 571,976 (0%) | 0% | 19.6 | 1,093,587 | Common Stock |
| Dr. Stelios Papadopoulos,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 20,718 | 1,260,329 (0%) | 0% | 0 | - | |
| Mr. Jack L. Wyszomierski, M.S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 20,718 | 338,185 (0%) | 0% | 0 | - | |
| Ms. Jacqueline Wright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 20,718 | 51,756 (0%) | 0% | 0 | - | |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 20,718 | 213,907 (0%) | 0% | 0 | - | |
| Dr. Maria C. Freire, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 20,718 | 80,419 (0%) | 0% | 0 | - | |
| Dr. Stelios Papadopoulos,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 20,718 | 1,260,329 (0%) | 0% | 0 | - | |
| Mr. Jack L. Wyszomierski, M.S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 20,718 | 338,185 (0%) | 0% | 0 | - | |
| Ms. Jacqueline Wright | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 20,718 | 51,756 (0%) | 0% | 0 | - | |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 20,718 | 213,907 (0%) | 0% | 0 | - | |
| Dr. Maria C. Freire, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 20,718 | 80,419 (0%) | 0% | 0 | - | |
| Mr. Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 18,176 | 18,176 (0%) | 0% | 0 | - | |
| Mr. Bob Oliver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 18,176 | 18,176 (0%) | 0% | 0 | - | |
| Mr. Tomas J. Heyman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 18,176 | 18,176 (0%) | 0% | 0 | - | |
| Mr. Bob Oliver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 18,176 | 18,176 (0%) | 0% | 0 | - | |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 15 May 2023 | 33,518 | 608,800 (0%) | 0% | 19.2 | 642,875 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 15 May 2023 | 4,940 | 579,003 (0%) | 0% | 19.2 | 94,749 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 15 May 2023 | 7,027 | 571,976 (0%) | 0% | 19.2 | 134,778 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 15 May 2023 | 10,002 | 571,631 (0%) | 0% | 19.2 | 191,838 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 15 May 2023 | 8,444 | 581,633 (0%) | 0% | 19.2 | 161,956 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 15 May 2023 | 8,765 | 316,020 (0%) | 0% | 19.2 | 168,113 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 15 May 2023 | 3,026 | 331,059 (0%) | 0% | 19.2 | 58,039 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 15 May 2023 | 6,274 | 324,785 (0%) | 0% | 19.2 | 120,335 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 15 May 2023 | 4,373 | 416,938 (0%) | 0% | 19.2 | 83,874 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 15 May 2023 | 6,115 | 410,823 (0%) | 0% | 19.2 | 117,286 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 313,185 | 642,318 (0%) | 0% | 0 | Common Stock | |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 03 Apr 2023 | 38,930 | 582,435 (0%) | 0% | 20.0 | 778,989 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 79,719 | 607,435 (0%) | 0% | 0 | Common Stock | |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.74 per share. | 03 Apr 2023 | 13,930 | 621,365 (0%) | 0% | 14.7 | 205,328 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | 03 Apr 2023 | 13,930 | 55,710 | - | - | Option (right to buy) | ||
| Mr. Christopher J. Senner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 85,414 | 590,077 (0%) | 0% | 0 | Common Stock | |
| Mr. Patrick J. Haley | EVP, Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 79,719 | 332,577 (0%) | 0% | 0 | Common Stock | |
| Ms. Vicki L. Goodman | EVP, Prod Dev & Med Aff &CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 82,566 | 307,654 (0%) | 0% | 0 | Common Stock | |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 68,331 | 419,803 (0%) | 0% | 0 | Common Stock | |
| Mr. Jack L. Wyszomierski, M.S. | Director | 10 Mar 2023 | 40,000 | 0 | - | - | Option (right to buy) | ||
| Mr. Jack L. Wyszomierski, M.S. | Director | Sale of securities on an exchange or to another person at price $ 16.61 per share. | 10 Mar 2023 | 15,300 | 317,467 (0%) | 0% | 16.6 | 254,133 | Common Stock |
| Mr. Jack L. Wyszomierski, M.S. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.30 per share. | 10 Mar 2023 | 40,000 | 332,767 (0%) | 0% | 6.3 | 252,000 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Sale of securities on an exchange or to another person at price $ 17.13 per share. | 01 Mar 2023 | 77,860 | 527,716 (0%) | 0% | 17.1 | 1,333,742 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | 01 Mar 2023 | 27,860 | 69,640 | - | - | Option (right to buy) | ||
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.74 per share. | 01 Mar 2023 | 27,860 | 605,576 (0%) | 0% | 14.7 | 410,656 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.70 per share. | 27 Feb 2023 | 10 | 351,482 (0%) | 0% | 14.7 | 147 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | 27 Feb 2023 | 82,490 | 0 | - | - | Option (right to buy) | ||
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | 27 Feb 2023 | 10 | 82,490 | - | - | Option (right to buy) | ||
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Sale of securities on an exchange or to another person at price $ 17.50 per share. | 27 Feb 2023 | 82,490 | 351,472 (0%) | 0% | 17.5 | 1,443,575 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.74 per share. | 27 Feb 2023 | 82,490 | 433,962 (0%) | 0% | 14.7 | 1,215,903 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Sale of securities on an exchange or to another person at price $ 17.50 per share. | 27 Feb 2023 | 10 | 351,472 (0%) | 0% | 17.5 | 175 | Common Stock |
| Dr. Alan M. Garber, M.D.,PhD | Director | Sale of securities on an exchange or to another person at price $ 17.49 per share. | 21 Feb 2023 | 40,000 | 31,417 (0%) | 0% | 17.5 | 699,600 | Common Stock |
| Dr. Alan M. Garber, M.D.,PhD | Director | 21 Feb 2023 | 40,000 | 0 | - | - | Option (right to buy) | ||
| Dr. Alan M. Garber, M.D.,PhD | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.30 per share. | 21 Feb 2023 | 40,000 | 71,417 (0%) | 0% | 6.3 | 252,000 | Common Stock |
| Dr. Michael M. Morrissey, PhD | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.08 per share. | 15 Feb 2023 | 11,522 | 329,133 (0%) | 0% | 18.1 | 208,318 | Common Stock |
| Mr. Jeffrey J. Hessekiel | EVP, General Counsel & Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.08 per share. | 15 Feb 2023 | 1,929 | 577,716 (0%) | 0% | 18.1 | 34,876 | Common Stock |
| Mr. Christopher J. Senner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.08 per share. | 15 Feb 2023 | 5,278 | 504,663 (0%) | 0% | 18.1 | 95,426 | Common Stock |
| Mr. Patrick J. Haley | EVP, Commercial | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.08 per share. | 15 Feb 2023 | 1,556 | 252,858 (0%) | 0% | 18.1 | 28,132 | Common Stock |
| Ms. Vicki L. Goodman | EVP, Prod Dev & Med Aff &CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.08 per share. | 15 Feb 2023 | 17,299 | 225,088 (0%) | 0% | 18.1 | 312,766 | Common Stock |
| Dr. Dana T. Aftab, PhD | CSO/EVP Disc & Trans Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.08 per share. | 15 Feb 2023 | 1,529 | 351,472 (0%) | 0% | 18.1 | 27,644 | Common Stock |
| Mr. Carl B. Feldbaum, Esq. | Director | Sale of securities on an exchange or to another person at price $ 17.78 per share. | 09 Feb 2023 | 40,000 | 18,701 (0%) | 0% | 17.8 | 711,200 | Common Stock |
| Mr. Carl B. Feldbaum, Esq. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.30 per share. | 09 Feb 2023 | 40,000 | 58,701 (0%) | 0% | 6.3 | 252,000 | Common Stock |